Overview

Evaluation of GLR2007 for Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Gan and Lee Pharmaceuticals, USA